Hangzhou Tigermed Consulting Co., Ltd.
$4.00+0.00%(+$0.00)
TickerSpark Score
67/100
77
Valuation
75
Profitability
70
Growth
84
Health
30
Momentum
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HNGZY research report →
52-Week Range0% of range
Low $4.00
Current $4.00
High $4.28
Companywww.tigermed.net
Hangzhou Tigermed Consulting Co. , Ltd. provides contract research organization services in the People's Republic of China and internationally.
- CEO
- Xiaoping Ye D.Phil
- IPO
- 2022
- Employees
- 10,185
- HQ
- Hangzhou, CN
Price Chart
+0.00% · this period
Valuation
- Market Cap
- $6.16B
- P/E
- 47.56
- P/S
- 4.69
- P/B
- 1.75
- EV/EBITDA
- 20.43
- Div Yield
- 0.67%
Profitability
- Gross Margin
- 26.64%
- Op Margin
- 17.97%
- Net Margin
- 10.91%
- ROE
- 3.69%
- ROIC
- 3.88%
Growth & Income
- Revenue
- $6.83B · 3.48%
- Net Income
- $887.89M · 119.15%
- EPS
- $1.04 · 121.28%
- Op Income
- $1.01B
- FCF YoY
- 22.05%
Performance & Tape
- 52W High
- $4.28
- 52W Low
- $4.00
- 50D MA
- $4.00
- 200D MA
- $4.00
- Beta
- 0.62
- Avg Volume
- 323.136
Get TickerSpark's AI analysis on HNGZY
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our HNGZY Coverage
We haven't published any research on HNGZY yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate HNGZY Report →